| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Propofol β-D-glucuronide does not target a specific biological receptor. It is the glucuronide conjugate of propofol, formed as a detoxification and elimination product. The compound is used in analytical chemistry as a reference standard to quantify propofol metabolism and to study glucuronidation pathways. It may also be used to assess UGT enzyme activity.
|
|---|---|
| ln Vitro |
In vitro, Propofol β-D-glucuronide is used as a reference standard in analytical methods such as HPLC or LC-MS/MS to measure propofol metabolism. It is also used in UGT enzyme activity assays, where its formation from propofol is measured to assess enzyme function. The compound itself is not biologically active and does not contribute to the anesthetic effects of propofol.
|
| ln Vivo |
In vivo, Propofol β-D-glucuronide is the major metabolite of propofol and is excreted in urine. It is used as a biomarker to monitor propofol metabolism and elimination in clinical and research settings. The compound's levels in plasma and urine can be measured to assess the pharmacokinetics of propofol and to study factors affecting its metabolism.
|
| Enzyme Assay |
Non-cellular assays for Propofol β-D-glucuronide involve its use as a reference standard in analytical chemistry. The compound's identity and purity are confirmed by HPLC, NMR, and mass spectrometry. It is used to calibrate analytical methods for the quantification of propofol and its metabolites in biological samples. The compound's stability in various matrices is also assessed.
|
| Cell Assay |
In vitro cellular experiments with Propofol β-D-glucuronide are limited, as the compound is not biologically active. It may be used in hepatocyte or liver microsome assays to study glucuronidation pathways, where its formation from propofol is measured. These assays are used to assess UGT enzyme activity and to study drug-drug interactions affecting propofol metabolism.
|
| Animal Protocol |
In vivo animal experiments with Propofol β-D-glucuronide involve measuring its levels in plasma, urine, or tissues following propofol administration. These studies are used to characterize the pharmacokinetics of propofol, to assess the impact of genetic or environmental factors on its metabolism, and to evaluate potential drug interactions.
|
| ADME/Pharmacokinetics |
Propofol β-D-glucuronide has a molecular formula of C18H26O7 and a molecular weight of 354.40. The CAS number is 114991-26-3. The compound is typically stored at -20°C and protected from light. It is soluble in methanol, DMSO, and other organic solvents. Purity is typically ≥95%. The compound is for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity data for Propofol β-D-glucuronide are not typically characterized as it is a metabolite and research reagent, not a therapeutic agent. Standard laboratory safety precautions should be followed when handling the compound. It is for research use only and not for human therapeutic applications.
|
| References | |
| Additional Infomation |
Propofol glucuronide is a glycoside.
Propofol β-D-glucuronide is the major inactive metabolite of propofol. It is used as a reference standard in pharmacokinetic studies and as a biomarker of propofol metabolism. All products are for research use only. |
| Molecular Formula |
C18H26O7
|
|---|---|
| Molecular Weight |
354.39
|
| Exact Mass |
354.168
|
| CAS # |
114991-26-3
|
| PubChem CID |
71751823
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.204
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
437
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC(C1C=CC=C(C(C)C)C=1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O)C
|
| InChi Key |
JZSJIASBMOIIKI-RUKPJNHUSA-N
|
| InChi Code |
InChI=1S/C18H26O7/c1-8(2)10-6-5-7-11(9(3)4)15(10)24-18-14(21)12(19)13(20)16(25-18)17(22)23/h5-9,12-14,16,18-21H,1-4H3,(H,22,23)/t12-,13-,14+,16-,18+/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R,6S)-6-[2,6-di(propan-2-yl)phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~30 mg/mL (~84.65 mM; with heating and sonication.)
DMF :~30 mg/mL (~84.65 mM; with heating and sonication.) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8218 mL | 14.1088 mL | 28.2175 mL | |
| 5 mM | 0.5644 mL | 2.8218 mL | 5.6435 mL | |
| 10 mM | 0.2822 mL | 1.4109 mL | 2.8218 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
